Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Panacea Life Sciences HoldingsPLSH -2.50% EV-to-OCF is -1.61 as of Aug. 09, 2026. The stock has 6 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Panacea Life Sciences Holdings ranks better than 73.58% on this metric.
The historical rank and industry rank for Panacea Life Sciences Holdings's EV-to-OCF or its related term are showing as below:
PLSH'
s EV-to-OCF Range Over the Past 10 Years
Min: -26.42 Med: -11.29 Max: -0.8
Current: -1.61
During the past 4 years, the highest EV-to-OCF of Panacea Life Sciences Holdings was -0.80. The lowest was -26.42. And the median was -11.29.
PLSH's EV-to-OCF is ranked better than 73.58% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 10.87
vs PLSH: -1.61
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Panacea Life Sciences Holdings (OTCPK:PLSH) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Panacea Life Sciences Holdings's PE Ratio (TTM) for today is calculated as:
Panacea Life Sciences Holdings's share price for today is $0.0975.
Panacea Life Sciences Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.030.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Panacea Life Sciences Holdings EV-to-OCF Related Terms
Panacea Life Sciences Holdings EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Panacea Life Sciences Holdings's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Panacea Life Sciences Holdings EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Panacea Life Sciences Holdings's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Panacea Life Sciences Holdings's EV-to-OCF falls into.
Panacea Life Sciences Holdings's current Enterprise Value is $2.30 Mil.
Panacea Life Sciences Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.43 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Panacea Life Sciences Holdings (PLSH) has a EV-to-OCF of -1.61 as of Aug. 09, 2026. According to the industry distribution chart, Panacea Life Sciences Holdings ranks #266 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 26.4%.
Is Panacea Life Sciences Holdings' EV-to-OCF too high?
Panacea Life Sciences Holdings' current EV-to-OCF is -1.61. Based on the distribution chart, Panacea Life Sciences Holdings ranks #266 out of 1007 companies in the Drug Manufacturers industry, which is above the industry midpoint.
How does Panacea Life Sciences Holdings' EV-to-OCF compare to SHPH and SKYI?
According to the Drug Manufacturers industry distribution chart, Panacea Life Sciences Holdings ranks #266 out of 1007 companies for EV-to-OCF. This puts Panacea Life Sciences Holdings in the upper half of its industry. The industry median EV-to-OCF is 10.87. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.87, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Panacea Life Sciences Holdings's current EV-to-OCF is -1.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panacea Life Sciences Holdings stock overvalued right now?
Panacea Life Sciences Holdings (PLSH) has a current EV-to-OCF of -1.61. The current EV-to-OCF is -1.61. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Panacea Life Sciences Holdings (PLSH), the current EV-to-OCF is -1.61 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Panacea Life Sciences Holdings Inc is a holding company organized as a plant-based natural health ingredient and product company, specializing in the development, manufacturing, research, and distribution of products and rapidly growing natural health and wellness market segment for both humans and animals. The company also offers the purest natural remedies within its branded product lines for every aspect of life: PANA Health, PANA Beauty, PANA Sport, PANA Pet, PANA Pure and PANA Life.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLSH has been successfully added to your 
